BridgeBio Oncology (BBOT) executive awarded 357K-option with 4-year vesting

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) reporting person Pedro Beltran, identified as an officer (Chief Scientific Officer) and director, received an option grant on 08/26/2025 to purchase 357,177 shares of common stock at an exercise price of $9.59 per share. The option is reported as acquired and is classified as a stock option with an expiration or reference date of 08/25/2035. Vesting begins from a Vesting Commencement Date of 08/11/2025: a pro rata fraction vests upon effectiveness of a Form S-8 registration and thereafter 1/48th vests monthly, completing over four years, subject to continuous service. The form is signed by an attorney-in-fact on 08/28/2025.

Positive

• Large option grant disclosed: 357,177-share option aligns executive incentives with long-term shareholder value
• Clear vesting schedule: Vesting commencement (08/11/2025) and monthly vesting over four years are specified
• Registration contingency disclosed: Partial vesting tied to Form S-8 effectiveness improves post-vest liquidity and compliance

Negative

• None.

Insights

Financial Analyst

TL;DR: Material insider option grant of 357,177 shares at $9.59 with a multiyear vesting schedule; routine compensation, not an immediate cash event.

The grant reported is a sizeable equity incentive for a senior scientific executive, aligning long-term interests with shareholders through multi-year vesting tied to a Form S-8 registration. The exercise price of $9.59 establishes the strike for potential future dilution if exercised. This disclosure does not reflect exercised or sold shares and therefore does not change outstanding share count today; it notifies investors of potential future dilution and compensation expense recognition over the vesting period.

Corporate Governance Expert

TL;DR: Standard governance disclosure for an option grant with conditional vesting; no governance red flags in the filing itself.

The Form 4 clearly discloses grant date, amount, exercise price, vesting commencement and the contingency tied to the S-8 filing. Vesting tied to a registration statement is common to enable resale post-registration. The filing is signed by an attorney-in-fact and includes the required vesting explanation, meeting disclosure norms for insider compensation transparency.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beltran Pedro

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.59	08/26/2025		A		357,177		(1)	08/25/2035	Common Stock	357,177	$0	357,177	D

Explanation of Responses:

1. A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

	/s/ Aaron Chan, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for BridgeBio Oncology Therapeutics (BBOT) disclose?

It disclosed that reporting person Pedro Beltran was granted a stock option to acquire 357,177 shares at an exercise price of $9.59 on 08/26/2025.

When does the option vest and what are the vesting conditions?

Vesting begins from the Vesting Commencement Date of 08/11/2025; a prorated fraction vests upon effectiveness of a Form S-8 and then 1/48th vests monthly thereafter until fully vested after four years, subject to continuous service.

Is the option immediately exercisable and what is the expiration reference?

The option is reported as acquired on 08/26/2025 with an expiration/reference date shown as 08/25/2035; exercisability is governed by the vesting schedule described in the filing.

Does this Form 4 show any sales or exercises by the reporting person?

No. The filing reports an acquisition of a derivative security (option). There are no reported dispositions or exercises in this Form 4.